Cargando…

MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma

Natural killer/T-cell lymphoma (NKTCL) is characterized by its highly aggressive nature and rapid progression. MicroRNAs (miRNAs) play key roles in the development of NKTCL. We utilized next-generation Solexa high-throughput sequencing to compare miRNA expression in the SNK-6 and YTS NKTCL cell line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xudong, Ji, Weiguo, Huang, Ruixia, Li, Lifeng, Wang, Xinhua, Li, Ling, Fu, Xiaorui, Sun, Zhenchang, Li, Zhaoming, Chen, Qingjiang, Zhang, Mingzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288223/ https://www.ncbi.nlm.nih.gov/pubmed/27462776 http://dx.doi.org/10.18632/oncotarget.10780

Ejemplares similares

Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma
por: Shi, Zhuangzhuang, et al.
Publicado: (2023)

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
por: Zhang, Xudong, et al.
Publicado: (2018)

Phosphatase and tensin homolog (PTEN) is down-regulated in human NK/T-cell lymphoma and corrects with clinical outcomes
por: Fu, Xiaorui, et al.
Publicado: (2017)

Utility of baseline, interim and end-of-treatment (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase
por: Chang, Yu, et al.
Publicado: (2017)

DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
por: Wang, Xin, et al.
Publicado: (2020)

Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report
por: HAN, LIJUAN, et al.
Publicado: (2014)

Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Shi, Zhuangzhuang, et al.
Publicado: (2021)

Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review
por: Lin, Li, et al.
Publicado: (2017)

T-cell dysfunction in natural killer/T-cell lymphoma
por: Feng, Xiaoyan, et al.
Publicado: (2023)

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
por: Du, Lijun, et al.
Publicado: (2020)

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma
por: Li, Zhaoming, et al.
Publicado: (2019)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

sATP-binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells
por: Wu, Shaoxuan, et al.
Publicado: (2020)

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
por: Zhang, Lei, et al.
Publicado: (2016)

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma
por: HAN, LIJUAN, et al.
Publicado: (2014)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
por: Ma, Xinran, et al.
Publicado: (2020)

Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers
por: Dong, Meng, et al.
Publicado: (2018)

Analyses and treatment of simultaneous bi-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review
por: Fu, Xiaorui, et al.
Publicado: (2018)

PB2388: ALTERATIONS OF THE GUT MICROBIOTA AS A NON-INVASIVE DIAGNOSTIC BIOMARKER FOR NATURAL KILLER/T-CELL LYMPHOMA
por: Shi, Zhuangzhuang, et al.
Publicado: (2023)

S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine
por: Zhou, Zhiyuan, et al.
Publicado: (2016)

AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma
por: Yan, Jiaqin, et al.
Publicado: (2018)

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma
por: Li, Ling, et al.
Publicado: (2018)

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial
por: Wu, Jingjing, et al.
Publicado: (2018)

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
por: Sun, Yuanyuan, et al.
Publicado: (2020)

Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B
por: Ge, Jun, et al.
Publicado: (2017)

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019)

PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma
por: Wu, Jiazhuo, et al.
Publicado: (2023)

CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3
por: Mei, Mei, et al.
Publicado: (2021)

Non-coding RNAs in Natural Killer/T-Cell Lymphoma
por: Mei, Mei, et al.
Publicado: (2019)

Updating targets for natural killer/T-cell lymphoma immunotherapy
por: Xue, Weili, et al.
Publicado: (2021)

B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma
por: Wang, Gangjian, et al.
Publicado: (2019)

The Emerging Role of MicroRNA-155 in Cardiovascular Diseases
por: Cao, Richard Y., et al.
Publicado: (2016)

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
por: Zhang, Lei, et al.
Publicado: (2016)

Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on (18)F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma
por: Feng, Xiaoyan, et al.
Publicado: (2021)

MicroRNA-155 expression with Brucella infection in vitro and in vivo and decreased serum levels of MicroRNA-155 in patients with brucellosis
por: Zhang, Xi, et al.
Publicado: (2022)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang, Fangwen, et al.
Publicado: (2019)

Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure
por: Hu, Junxia, et al.
Publicado: (2021)

OLFML3 Expression is Decreased during Prenatal Muscle Development and Regulated by MicroRNA-155 in Pigs
por: Zhao, Shuanping, et al.
Publicado: (2012)

B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma
por: Shang, Yufeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ig9qvi9fdgv1vuvobnq7v6o8qo